About Jon

Jon focuses on developing and executing worldwide patent strategies for life sciences and pharmaceutical companies. He counsels clients on drug design, life cycle extension strategies, clinical trial inventions and Orange Book listing strategies. Notable patent portfolios Jon has worked on include Epidiolex, Copiktra, Farydak, Arikayce, Amrix, Lamictal and Evekeo ODT, as well as numerous candidates in clinical trials.

Passions

Skiing

Fly-fishing

Staying active

Family

View full bio

Experience

View more

Admissions and credentials

  • Montana
  • District of Columbia
  • Registered to practice before the United States Patent and Trademark Office (USPTO)

Rankings and accolades

The Legal 500 US: Patents: Prosecution (Including Re-Examination and Post-Grant Proceedings) (2021, 2025)

Best Lawyers: Ones to Watch – Patent and IP, 2024

Concurrences: Readers’ Choice Antitrust Writing Award for Intellectual Property, 2024

Memberships and affiliations

  • American Intellectual Property Law Association

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.